Analyst firms · H.C. Wainwright · TRVI

H.C. Wainwright TRVI price target and rating history

Trevi Therapeutics Inc. (TRVI) · Health Care

H.C. Wainwright rates Trevi Therapeutics Inc. (TRVI) Buy with a $21 price target, as of its latest action on May 28, 2025. It has published 3 rating actions on TRVI since August 2024, including 0 upgrades and 0 downgrades.

Current rating
Buy
Price target
$21
Median target, all firms
Too few
Actions on TRVI
3

H.C. Wainwright price target on TRVI

$21$14$620252026
H.C. Wainwright price target on TRVI, each point a stated target, August 2024 to May 2025.

Every H.C. Wainwright rating on TRVI

Questions about H.C. Wainwright and TRVI

What is H.C. Wainwright's price target for TRVI?
H.C. Wainwright's latest stated price target for Trevi Therapeutics Inc. (TRVI) is $21, from its action on May 28, 2025.
What is H.C. Wainwright's rating on TRVI?
H.C. Wainwright rates TRVI Buy, a bullish rating, as of May 28, 2025.
When did H.C. Wainwright last change its view on TRVI?
On May 28, 2025, H.C. Wainwright starts coverage at Buy, price target $21.

More TRVI rating histories

All H.C. Wainwright ratingsTRVI news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.